Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced financial results for …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Hold rating on Endocyte (NASDAQ:ECYT), as the company released its third-quarter …
In a research published today, Brean Capital analyst Jonathan Aschoff downgraded shares of Endocyte (NASDAQ:ECYT) from a Buy to a Hold rating, on …
In a research note released today, Wedbush analyst David M. Nierengarten reiterated an Outperform rating on Endocyte (NASDAQ:ECYT) with a $26 price target, …
